TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03584763

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical artery Doppler
Description: Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler
Description: Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
Study: NCT03650946

Intervention type: DIAGNOSTIC_TEST
Intervention: Ga-68 PSMA PET
Description: Ga-68 PSMA PET

Intervention type: DIAGNOSTIC_TEST
Intervention: Ga-68 PSMA PET
Description: Ga-68 PSMA PET
Study: NCT02933671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprainguinal fascia iliaca (SIFI) block
Description: An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
Study: NCT01690845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MARS
Description: Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
Study: NCT04349137

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tACS
Description: non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tACS
Description: non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS) low intensive electrical alternating currents (2 mA peak-to-peak) are externally applied to the skull at a frequency of 6Hz to entrain endogenous neural oscillatory activity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham HD-tACS
Description: sham non-invasive high-definition dual-site transcranial alternating current stimulation (HD-tACS)
Study: NCT02582996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
Description: The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
Study: NCT03629301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ID-DPP group
Description: This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list Group
Description: This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
Study: NCT02933671

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham block
Description: An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic (numbing drug)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Salt water placebo
Study: NCT01511055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-17
Description: One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
Study: NCT03699969

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated dose escalated VMAT
Description: measure the local control, progression free survival and overall survival
Study: NCT04982601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Exercises
Description: Yoga-based exercises are Hatha yoga-based sessions consisting of breathing exercises, warm-up exercises, relaxation, asanas exercises.
Study: NCT01027273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent Return of Stroke
Description: Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevent Return of Stroke
Description: The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
Study: NCT03689907

Intervention type: OTHER
Intervention: Chimerism Evaluation
Description: Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
Study: NCT02507960

Intervention type: DEVICE
Group type: OTHER
Intervention: The Gamma Pod
Description: Immobilization of breast during radiation.

Intervention type: DEVICE
Group type: OTHER
Intervention: CT simulation
Description: See arm description
Study: NCT01528865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks.
Study: NCT02335658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5423P
Description: 40-80mg/day
Study: NCT04643197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed PDS suture (STRATAFIX Symmetric PDS Plus)
Description: STRATAFIX Symmetric PDS Plus is a barbed suture.
Study: NCT02758470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg, taken orally three times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Description: 100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be taken three times per day
Study: NCT01668043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody UB-421
Description: UB-421 is administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibody UB-421
Description: UB-421 is administered by intravenous infusion
Study: NCT03050567

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler Ultrasound
Description: Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler Ultrasound
Description: Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
Study: NCT02331732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtually Observed Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Directly Observed Treatment
Study: NCT03336970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDTA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDTA
Study: NCT03996447

Intervention type: DRUG
Group type: OTHER
Intervention: gadopiclenol
Description: single intravenous (IV) bolus injection at a rate of 2ml/second

Intervention type: DRUG
Group type: OTHER
Intervention: gadopiclenol
Description: single intravenous (IV) bolus injection at a rate of 2ml/second

Intervention type: DRUG
Group type: OTHER
Intervention: Gadobutrol 1Mmol/mL Solution for Injection Vial
Description: single intravenous (IV) bolus injection at a rate of 2ml/second

Intervention type: DRUG
Group type: OTHER
Intervention: Gadobutrol 1Mmol/mL Solution for Injection Vial
Description: single intravenous (IV) bolus injection at a rate of 2ml/second
Study: NCT01762514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine every-other-day regimen
Description: Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine every-other-day regimen
Description: Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine everyday regimen
Description: Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine everyday regimen
Description: Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
Study: NCT01427309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03047499

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum toxin type-A injection

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum toxin type-A injection

Intervention type: DRUG
Intervention: Botulinum toxin type A
Description: Botulinum toxin type-A injection
Study: NCT00351364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast Sodium
Description: 100 mg P.O. One time only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium
Description: 100 mg P.O. One time only
Study: NCT03336970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NaOCl
Study: NCT03617705

Intervention type: DEVICE
Group type: OTHER
Intervention: Skyn Monitor Lab Session 1
Description: Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.

Intervention type: DEVICE
Group type: OTHER
Intervention: Skyn Monitor Field Test with EMA App
Description: After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.

Intervention type: DEVICE
Group type: OTHER
Intervention: Skyn Monitor Lab Session 2
Description: Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
Study: NCT04643197

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-barbed PDS suture (PDS Plus)
Description: Non-barbed suture
Study: NCT00846274

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SK Antithrombin III

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SK Antithrombin III
Study: NCT00798447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLF 541
Description: 22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipofundin MCT
Description: 22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
Study: NCT05239819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The initial training intensity of the preoperative threshold IMT trainer (DofinTM, Breathing Strength Builder, Taiwan) was moderate to high intensity (≥50% of MIP), which was according to the patient's baseline level and increased by 5-10% per week. The frequency is 25-30 minutes each time, twice a day and five days per week for at least two weeks. The participants would receive at least 10 times training sessions before surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regulated care and education
Description: Regulated care and education will be applied
Study: NCT04017156

Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant installation
Description: All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
Study: NCT00733902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg at 1 dose every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg at 1 dose every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 2.5 mg at 1 dose every 8 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV placebo to match tanezumab at 1 dose every 8 weeks
Study: NCT00928070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4 mg and 8 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sham 4 mg and 8 mg
Study: NCT02891421

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Therapeutic Horseback Riding
Description: Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard Care: Participants received standard care
Study: NCT01849926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT04017156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant installation
Description: All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
Study: NCT01849926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecillinam
Study: NCT04274439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Pain Education and Exercise
Description: Telerehabilitation is defined as providing techniques for therapeutic rehabilitation remotely or off-site using telecommunication technologies. Thus, our intervention will be based on the use of a website created and registered especially for the study that will have the shooting of 1 video of pain education and 1 video of exercises for the subjects of the study, totaling 8 videos of pain education and 8 exercise videos. We will provide complimentary materials along with the triggered videos and a booklet of chronic pain information. We will also make weekly calls for a health coaching service and the sending of smartphone messages for the motivation and accountability of the subjects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Booklet
Description: An online booklet containing information about chronic pain and suggestions for lifestyle modifications and behavior will be delivered, as well as an incentive to perform physical exercises.
Study: NCT01767402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhtD vaccine with/without adjuvant
Description: Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhtD vaccine with/without adjuvant
Description: Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhtD vaccine with/without adjuvant
Description: Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhtD vaccine with/without adjuvant
Description: Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PhtD vaccine with/without adjuvant
Description: Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23TM
Description: One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NaCl
Description: One dose administered intramuscularly in the deltoid region of the right arm at month 2.
Study: NCT06423248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culinary spices
Description: Powdered culinary spices

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culinary spices
Description: Powdered culinary spices

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Culinary spices
Description: Powdered culinary spices

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Culinary spices
Description: Powdered culinary spices
Study: NCT03763786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate
Description: Used a standard

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix Acetate
Description: Used a standard
Study: NCT01491178

Intervention type: DRUG
Intervention: Prazaxa
Description: Dabigatran etexilate
Study: NCT04807894

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Cream with Applicator
Description: Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Cream with Applicator
Description: Vaginal testosterone 300-μg dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.